Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Seinda Pharmaceutical Guangzhou Corporation has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners but are concentrated within 1 distinct art unit. This suggests that the company's current patent applications are technically related.
The busiest examiner is ESPINOSA, CLAUDIA EDILMA, who is handling 1 pending office action. Since there are 2 distinct examiners for 2 pending office actions, the workload is split evenly. This requires the company to manage relationships with 2 different individuals at the patent office simultaneously.
The use of 1 distinct art unit for 2 pending office actions may allow for some consistency in the technical standards applied during examination. However, the involvement of 2 distinct examiners means that the company must still adapt to different individual perspectives. This balanced distribution of 2 pending office actions highlights a focused yet multi-examiner prosecution strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +57.7% |
| KOMATSU, LI N | 1 | 59.8% | +71.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18715086 | NOVEL USE OF ALANYL-GLUTAMINE AND OPHTHALMIC COMPOSITION COMPRISING ALANYL-GLUTAMINE | ESPINOSA, CLAUDIA EDILMA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18518134 | OPHTHALMIC PHARMACEUTICAL COMPOSITION AND ITS PREPARATION METHODS AND APPLICATIONS | KOMATSU, LI N | 17d overdue |
| 18715086 | NOVEL USE OF ALANYL-GLUTAMINE AND OPHTHALMIC COMPOSITION COMPRISING ALANYL-GLUTAMINE | ESPINOSA, CLAUDIA EDILMA | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18715086 | NOVEL USE OF ALANYL-GLUTAMINE AND OPHTHALMIC COMPOSITION COMPRISING ALANYL-GLUTAMINE | ESPINOSA, CLAUDIA EDILMA | — | §102§112 | Non-Final OA | — | Pending | May 30, 2024 |
| 18518134 | OPHTHALMIC PHARMACEUTICAL COMPOSITION AND ITS PREPARATION METHODS AND APPLICATIONS | KOMATSU, LI N | 1658 | DP | Final Rejection | 17d overdue | Pending | Nov 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial